Persist AI raises $12M in Series A funding to launch its Cloud Lab for accelerating pharmaceutical formulation development, led by Spero Ventures.
Persist AI raises $12M in Series A funding to launch its Cloud Lab for accelerating pharmaceutical formulation development, led by Spero Ventures.
05/19/25, 4:45 PM
Location
west sacramentoMoney raised
$12 million
Industry
health care
Investors
Y Combinator, Innospark, 2048 Ventures, Asymmetry Ventures, Cartography Capital, Good Ai Capital, Purdue Ventures, Ford Street Capital, Signal Fire, Eli Lilly & Company, Shimadzu Future Innovation Fund Managed By Global Brain Corporation, Mbx Capital, Spero Ventures
Persist AI announced the launch of its Cloud Lab platform after raising $12 million in an oversubscribed Series A financing round. The platform enables pharmaceutical companies to accelerate drug formulation development using advanced robotics. This funding round was led by Spero Ventures, alongside multiple other investors. The investment aims to lower the hurdles in developing next-generation therapeutics.
Company Info
Location
890 embarcadero dr.
west sacramento, california, united states
Additional Info
Persist AI is revolutionizing pharmaceutical development through AI-driven robotics for formulation development and CMC. By combining predictive AI models with automated robotic systems, Persist AI enables pharmaceutical companies to develop drug formulations in a fraction of the time and cost of traditional approaches. The company works across multiple modalities and formulation types to accelerate bringing novel therapeutics to patients. Persist AI is a Y Combinator-backed company, having graduated from the prestigious startup accelerator in 2023.